Imonogas + Espumisan
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Dyspepsia
Conditions
Functional Dyspepsia
Trial Timeline
Feb 1, 2016 → Dec 1, 2016
NCT ID
NCT02660372About Imonogas + Espumisan
Imonogas + Espumisan is a phase 3 stage product being developed by Johnson & Johnson for Functional Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT02660372. Target conditions include Functional Dyspepsia.
What happened to similar drugs?
0 of 5 similar drugs in Functional Dyspepsia were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02660372 | Phase 3 | Completed |
Competing Products
20 competing products in Functional Dyspepsia